In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.
about
Multifaceted functions and roles of HBZ in HTLV-1 pathogenesisRoles of HTLV-1 basic Zip Factor (HBZ) in Viral Chronicity and Leukemic Transformation. Potential New Therapeutic Approaches to Prevent and Treat HTLV-1-Related DiseasesModes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and PersistenceRegulation of human T-lymphotropic virus type I latency and reactivation by HBZ and Rex.HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.Expansion in CD39⁺ CD4⁺ immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications.Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infectionCytotoxic T lymphocyte lysis of HTLV-1 infected cells is limited by weak HBZ protein expression, but non-specifically enhanced on induction of Tax expression.Massive depletion of bovine leukemia virus proviral clones located in genomic transcriptionally active sites during primary infection.Human T-cell lymphotropic virus: a model of NF-κB-associated tumorigenesisThe HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATLCytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).HTLV-1 drives vigorous clonal expansion of infected CD8(+) T cells in natural infection.Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectivesAbsolute quantification of HTLV-1 basic leucine zipper factor (HBZ) protein and its plasma antibody in HTLV-1 infected individuals with different clinical status.Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs.Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection.Inflammatory manifestations of HTLV-1 and their therapeutic options.Integration site and clonal expansion in human chronic retroviral infection and gene therapy.The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.Human T-cell leukaemia virus type 1: parasitism and pathogenesis.Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibodyReevaluation of confirmatory tests for human T-cell leukemia virus Type 1 using a luciferase immunoprecipitation system in blood donors.Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?Single-cell heterogeneity and cell-cycle-related viral gene bursts in the human leukaemia virus HTLV-1.Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP.HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases.
P2860
Q26765424-5213591E-A13F-4DD1-8960-09212C84BA0EQ26774352-7F25CB32-6D80-4FEF-A4F8-5A15275FC885Q26801294-28903BD2-9EB3-4B9C-BA7A-57F26BE2E560Q31156885-1D050789-8A39-4FF2-BCAB-CF23DBA1A73EQ34316662-1C438958-4769-4A55-96C5-06FF2E5C278DQ34587031-5C966E96-C0F9-4465-B27A-6AD1FE30D192Q34649734-D236D56C-AD81-4CEC-8170-FE69E0BF84FDQ34808201-9C8C2748-451C-4B96-8586-2625B2FCF56FQ35008829-B9F44A2F-B21E-4177-9BFD-73C1F5E53864Q35090534-A5848586-61E2-41CB-8E6F-12DF3D34D5F0Q35105393-B5B2DE57-7678-49F6-9844-5DBB3451D7FAQ35261463-2169B680-2041-4FB9-BBC8-2657356F56F3Q35816954-A576643A-2A38-4219-BC0E-9B504C5E439BQ36251464-D2A7E448-D3C3-4A51-8DA4-50659BD63320Q36267687-50DBEF83-8F53-47BD-9B67-4E60AA99416CQ36422111-9F50D8A0-7FEA-4785-99F9-F5DF830E18F8Q36842571-FEB20E04-FA59-49B9-9853-3A9A480586CBQ37625483-7889D438-43CB-4FC3-B9B8-9DCD5EECBD28Q38128799-B6300EEF-0281-4E9E-A122-ABA640029032Q38169485-83163B9B-CC36-4DDA-83F7-22DFED9D7CD0Q38262169-B2D8B249-110E-4764-9FF8-7D2DE6AC616EQ38264568-C67AF817-4393-423A-8AD9-BE6BC469C00FQ39119670-172AD35B-57F7-4114-976A-752F6644BBA0Q40046615-7314C34B-261F-4661-A8B4-AFEFC9FB3DD4Q40649807-6F6C83BC-7C29-43C1-A7EF-1DEB0CC4C4DCQ41680441-8990EAA6-AA1B-49EB-B819-F8D82907C62EQ41723007-8AA3DFC2-25E6-4648-BF52-7133199E1690Q43259362-E019B013-2395-48E4-BB84-AC90FAAB11EBQ47201640-B12BEEF0-235F-4ADC-86FB-189606436DF7Q47221371-DD8EEF9D-F46A-4E21-902E-73F53D926856
P2860
In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vivo expression of human T- ...... rrelate with clinical outcome.
@ast
In vivo expression of human T- ...... rrelate with clinical outcome.
@en
In vivo expression of human T- ...... rrelate with clinical outcome.
@nl
type
label
In vivo expression of human T- ...... rrelate with clinical outcome.
@ast
In vivo expression of human T- ...... rrelate with clinical outcome.
@en
In vivo expression of human T- ...... rrelate with clinical outcome.
@nl
prefLabel
In vivo expression of human T- ...... rrelate with clinical outcome.
@ast
In vivo expression of human T- ...... rrelate with clinical outcome.
@en
In vivo expression of human T- ...... rrelate with clinical outcome.
@nl
P2093
P2860
P356
P1476
In vivo expression of human T- ...... rrelate with clinical outcome.
@en
P2093
Charles R M Bangham
Graham P Taylor
Maria-Antonietta Demontis
Silva Hilburn
P2860
P304
P356
10.1093/INFDIS/JIQ078
P407
P577
2011-01-05T00:00:00Z